Technology Bundle ID: TAB-2022

Biological/Research Material for H1N1 Influenza Virus Vaccine Research

Request More Info
Licensing Contact:
Primary Inventors: 
Bernard Moss (NIAID)
Linda Wyatt (NIAID)
Therapeutic Area: 
Infectious Disease
Research Materials
Development Status: 

Fully developed. The usefulness of the materials has been shown in Dr. Moss' laboratory.

Institute or Center: 

Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice.

The materials can be used for research purposes and in particular in the area of influenza virus vaccines.

The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research.

  • Research reagents useful in research and development in the area of H1N1 Influenza virus vaccines.

CB Process - Initiated CB Process. Forwarded email to LPM. Requesting details concerning the new technology.


EIR Application

Research Material - Patent protection is not being pursued for this technology.


Bender B, et al.
PMID 8709274
Sutter G, et al.
PMID 7975844


Oct 12, 2009

Data Source: